Skip to main content
Terug
Watch Compare

Advanced Biomed Inc.

Datakwaliteit: 83%
ADVB
NASDAQ Services Health Services
€ 6,60
▼ € 0,09 (-1,35%)
Marktkapitalisatie: 8,90 M
Prijs
€ 6,52
Marktkapitalisatie
8,90 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

ROE of 70,25% indicates high profitability
Negative free cash flow of -6,11 M
P/E of 2,03 — trading at a low valuation

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
70,25%
Boven sectorgemiddelde (-15,97%)
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio8,56
Interest CoverageN/A

Waardering

PE (TTM)
2,03
Boven sectorgemiddelde (-1,19)
P/B Ratio0,94
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Services sector mediaan (515 peers)
Metriek Aandeel Sector Mediaan
P/E 2,0 -1,2
P/B 0,9 1,4
ROE % 70,3 -16,0
Net Margin % — -19,4
Rev Growth 5Y % — 4,2
D/E — 0,4

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) 4,39 M
ROE 70,25% ROA 51,31%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -6,11 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8,56
Interest Coverage N/A Asset Turnover N/A
Working Capital 9,48 M Tangible Book Value 9,48 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 2,03 Forward P/E N/A
P/B Ratio 0,94 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -68,67%
Market Cap 8,90 M Enterprise Value 8,90 M
Per Share
EPS (Diluted TTM) 0,20 Revenue / Share N/A
FCF / Share -4,48 OCF / Share -4,45
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion -139,42%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025
Revenue —
Net Income -3,26 M
EPS (Diluted) -0,16
Gross Profit —
Operating Income —
EBITDA —
R&D Expenses 909.771,0
SG&A Expenses —
D&A 343.830,0
Interest Expense —
Income Tax —

Balance Sheet

Annual, most recent first
Metric FY2025
Total Assets 6,51 M
Total Liabilities 3,03 M
Shareholders' Equity 3,48 M
Total Debt —
Cash & Equivalents —
Current Assets 6,03 M
Current Liabilities 2,89 M